Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $142

Citigroup analyst Samantha Semenkow has reaffirmed a Buy rating on Rhythm Pharmaceuticals (NASDAQ: RYTM) and increased the price target from $131 to $142. This adjustment reflects positive expectations for the company's performance in the market.